EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Persistence of an Infectious Form of SARS-CoV-2 After Protease Inhibitor Treatment of Permissive Cells In Vitro

Manoj S Nair iD, Maria I Luck, Yaoxing Huang, Yosef Sabo iD, David D Ho iD

The Journal of Infectious Diseases · 2025

DOI: 10.1093/infdis/jiae385 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Manoj S Nair und 4 weiteren Autor:innen. Beteiligte Einrichtung: Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA. Hauptthemen laut MEDLINE: SARS-CoV-2, Antiviral Agents, COVID-19 Drug Treatment, Protease Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Andrew and Peggy Cherng, Samuel Yin, Barbara Picower.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Reports have described severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rebound in coronavirus disease 2019 (COVID-19) patients treated with nirmatrelvir, a 3CL protease inhibitor. The cause remains a mystery, although drug resistance, reinfection, and lack of adequate immune responses have been excluded. We now present virologic findings that provide a clue to the cause of viral rebound, which occurs in approximately 20% of the treated cases. Persistence of infectious SARS-CoV-2 was experimentally documented in vitro after treatment with nirmatrelvir or another 3CL protease inhibitor, but not with a polymerase inhibitor, remdesivir. This infectious form decayed slowly with a half-life of approximately 1 day, suggesting that its persistence could outlive the treatment course to reignite SARS-CoV-2 infection as the drug is eliminated. Notably, extending nirmatrelvir treatment beyond 8 days abolished viral rebound in vitro. Our findings point in a particular direction for future investigation of virus persistence and offer a specific treatment recommendation that should be tested clinically.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2Antiviral AgentsCOVID-19 Drug TreatmentProtease InhibitorsHumansAlanineCOVID-19Chlorocebus aethiopsAdenosine MonophosphateVero CellsAnimalsProlineIndolesLactamsLeucineNitriles

Stichwörter der Autor:innen

SARS-CoV-2nirmatrelvirprotease inhibitorreboundvirus persistence

Substanzen

Antiviral AgentsProtease InhibitorsnirmatrelvirAlanineremdesivirAdenosine MonophosphateProlineIndolesLactamsLeucine

Autor:innen und Institutionen

  • Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA.
  • Division of Infectious Diseases, Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA.
  • Department of Microbiology and Immunology, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA.

ORCID-Profile: Manoj S Nair, Yosef Sabo, David D Ho

Förderung

  • Andrew and Peggy Cherng
  • Samuel Yin
  • Barbara Picower
  • JPB Foundation
  • Roger and David Wu
  • Bill and Melinda Gates Foundation
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Nair, M. S., Luck, M. I., Huang, Y., Sabo, Y., & Ho, D. D. (2025). Persistence of an Infectious Form of SARS-CoV-2 After Protease Inhibitor Treatment of Permissive Cells In Vitro. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae385

Vancouver

Nair MS, Luck MI, Huang Y, Sabo Y, Ho DD. Persistence of an Infectious Form of SARS-CoV-2 After Protease Inhibitor Treatment of Permissive Cells In Vitro. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiae385

BibTeX
@article{Nair2025,
  author = {Nair, Manoj S and Luck, Maria I and Huang, Yaoxing and Sabo, Yosef and Ho, David D},
  title = {Persistence of an Infectious Form of SARS-CoV-2 After Protease Inhibitor Treatment of Permissive Cells In Vitro},
  journal = {The Journal of Infectious Diseases},
  year = {2025},
  doi = {10.1093/infdis/jiae385}
}
Kostenlos starten →